Lv1
40 积分 2026-01-10 加入
Abstract GS2-05: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials
2个月前
已关闭
Efficacy and safety of giredestrant (GIRE) in patients (pts) with estrogen receptor–positive, HER2-negative early breast cancer (ER+, HER2– eBC) in the phase III lidERA BC clinical trial: Results by menopausal status
2个月前
已关闭
A foundation model for predicting outcomes of neoadjuvant chemotherapy in breast cancer
7个月前
已完结
皖公网安备34019202002308
